Abstract
Transvaginal ultrasonography (TVS) is an integral part of all major ovarian cancer screening trials. TVS is accurate in detecting abnormalities in ovarian volume and morphology, but is less reliable in differentiating benign from malignant ovarian tumors. When used as the only screening test, TVS is sensitive, but has a low positive predictive value. Therefore, serum biomarkers and tumor morphology indexing are used together with TVS to identify ovarian tumors at high risk for malignancy. This allows preoperative triage of high-risk cases to major cancer centers for therapy while decreasing unnecessary surgery for benign disease. Ovarian cancer screening has been associated with a decrease in stage at detection in most trials, thereby allowing treatment to be initiated when the disease is most curable.
Document Type
Review
Publication Date
12-20-2013
Digital Object Identifier (DOI)
http://dx.doi.org/10.2147/IJWH.S38347
Repository Citation
van Nagell, John R. Jr. and Hoff, John T., "Transvaginal Ultrasonography in Ovarian Cancer Screening: Current Perspectives" (2013). Obstetrics and Gynecology Faculty Publications. 6.
https://uknowledge.uky.edu/obgyn_facpub/6
Notes/Citation Information
Published in International Journal of Women's Health, v. 6, p. 25-33.
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php